Chemokine Like Receptor-1 (CMKLR-1) Receptor: A Potential Therapeutic Target in Management of Chemerin Induced Type 2 Diabetes Mellitus and Cancer

Author(s): Sangeetha Perumalsamy, Nurul Ain Aqilah Mohd Zin, Riyanto Teguh Widodo, Wan Azman Wan Ahmad, Shireene Ratna D.B. Vethakkan, Hasniza Zaman Huri*

Journal Name: Current Pharmaceutical Design

Volume 23 , Issue 25 , 2017

Become EABM
Become Reviewer
Call for Editor


Background: Chemerin is an adipokine that induces insulin resistance by the mechanism of inflammation in adipose tissue but these are still unclear. A high level of chemerin in humans is considered as a marker of inflammation in insulin resistance and obesity as well as in type 2 diabetes mellitus. Despite the role of chemerin in insulin resistance progression, chemerin as one of the novel adipokines is proposed to be involved in high cancer risk and mortality.

Aim: The aim of this paper was to review the role of CMKLR-1 receptor and the potential therapeutic target in the management of chemerin induced type 2 diabetes mellitus and cancer.

Pathophysiology: Increased chemerin secretion activates an inflammatory response. The inflammatory response will increase the oxidative stress in adipose tissue and consequently results in an insulin-resistant state. The occurrence of inflammation, oxidative stress and insulin resistance leads to the progression of cancers.

Conclusion: Chemerin is one of the markers that may involve in development of both cancer and insulin resistance. Chemokine like receptor- 1 (CMKLR-1) receptor that regulates chemerin levels exhibits a potential therapeutic target for insulin resistance, type 2 diabetes and cancer treatment.

Keywords: Chemerin, insulin resistance, type 2 diabetes mellitus, cancer, chemokine-like receptor 1, therapeutic target, obesity, inflammation.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2017
Published on: 15 June, 2017
Page: [3689 - 3698]
Pages: 10
DOI: 10.2174/1381612823666170616081256
Price: $65

Article Metrics

PDF: 44